Shares of TerrAscend Corp. (TSNDF Quick QuoteTSNDF - Free Report) have gained about 6% over the past month, reflecting improving operating performance and growing investor interest in the U.S. cannabis sector. The company recently reported second-quarter results that showed year-over-year revenue growth, higher gross margins and stronger adjusted EBITDA.

However, investors typically look beyond a single quarter and assess whether these improvements can be sustained. With revenue growth returning, margins strengthening and several potential catalysts ahead, TerrAscend’s outlook appears more constructive, although pricing pressure, debt and intense competition remain concerns.

Let’s take a closer look at the company’s fundamentals to assess whether the recent rally is justified.

TSNDF’s Revenue & Margins Show Signs of Improvement

TerrAscend’s revenue trend has improved in 2026 after sales declined in 2025. The company returned to year-over-year growth in both the first and second quarters, helped by stronger performance across its core Northeast markets. Pennsylvania has been a notable contributor, with revenues increasing for a third consecutive quarter in Q2, while New Jersey and Maryland also continued to post sequential growth. The company brought additional cultivation capacity online in Pennsylvania and recently expanded its New Jersey retail footprint with the addition of Aunt Mary’s, giving it more capacity to serve both retail and wholesale demand.

These trends are reflected in TerrAscend’s first-half 2026 results. Revenues from continuing operations increased 2.6% to $132.7 million in the first six months of 2026 from $129.3 million a year earlier. Q1 revenues increased 1.9% year over year, while Q2 revenues rose 3.3% to $67.1 million and increased 2.4% sequentially, with both retail and wholesale sales contributing to the quarterly improvement.

Beyond the top line, TerrAscend has also been making progress on margins. Gross margin was at 54%, up 290 basis points (bps) over the year-ago period and 120 bps sequentially, with management attributing the improvement primarily to operational execution and greater vertical integration across its core markets rather than a broad improvement in cannabis pricing. Stronger product quality, customer retention and higher verticality have helped the company manage pricing pressure across its markets.

Though adjusted EBITDA margin for second-quarter 2026 declined 20 bps sequentially to 26.3%, it was up 170 bps over the year-ago period. TerrAscend also continued to generate positive cash flow, reporting $7.4 million of operating cash flow and $5.7 million of free cash flow in Q2, marking its 16th consecutive quarter of positive operating cash flow and 12th consecutive quarter of positive free cash flow. With qualifying medical cannabis no longer subject to Section 280E, the change could further improve profitability and cash generation.

Looking ahead, management expects the sales momentum to continue, forecasting 2-3% year-over-year revenue growth in Q3 2026. While this points to continued expansion, the pace remains modest, making sustained growth across TerrAscend’s core markets increasingly important to the investment story. Management also remains confident that gross margin can stay within the 52-54% range for the remainder of 2026 and is targeting 25-26% adjusted EBITDA margins, with inventory, pricing pressure and competitive intensity among the key variables that could affect performance.

TSNDF Advances Its Potential U.S. Uplisting

TerrAscend has continued to make progress toward a potential listing on a major U.S. stock exchange. The company has said it is in active discussions with NASDAQ and the NYSE and is taking the steps needed to meet their listing requirements. As part of that process, shareholders recently approved a share consolidation in the range of 1-for-5 to 1-for-20, giving the board discretion to determine the exact ratio and timing.

The approval removes an important procedural step, but it does not mean that TerrAscend has completed an uplisting. The company still needs to satisfy the applicable exchange requirements and determine whether and when to implement the consolidation. Management has indicated that broader federal cannabis reform could further support its efforts to access a major U.S. exchange.

Debt Remains Elevated

TerrAscend has made some progress in managing its debt, although leverage remains an important consideration for investors. During the second quarter of 2026, the company refinanced a portion of its near-term convertible debt, using $11.1 million of new convertible financing to retire higher-interest obligations. The new convertible debentures mature in 2031, extending the maturity profile and reducing the immediate refinancing burden. TerrAscend used its cash flow to repay another $10 million of term-loan principal during the quarter, bringing total term-loan repayments for the first half of 2026 to $15.5 million.

The balance sheet therefore looks somewhat better positioned from a maturity perspective, but the company remains meaningfully leveraged. As of June 30, total debt, net, was approximately $197.3 million, down from $209.2 million at the end of 2025, while cash increased to $42 million from $37.4 million. Management also said there are no material debt maturities until the second half of 2028, which provides some additional financial flexibility.

Competition Remains Intense

TerrAscend continues to operate in a highly competitive U.S. cannabis market, where larger multi-state operators are expanding their retail footprints and branded-product businesses. Curaleaf Holdings (CURLF Quick QuoteCURLF - Free Report) and Green Thumb Industries (GTBIF Quick QuoteGTBIF - Free Report) remain two notable competitors, with both operating across many of the same major U.S. markets and continuing to invest in retail, brands and production capacity.

Both companies have established retail and cannabis operations across multiple states, with the majority of their revenues generated in the United States. Curaleaf has also been expanding its presence in international markets, giving it an additional source of revenue beyond its core U.S. operations. The scale and geographic reach of these operators add to the competitive pressure TerrAscend faces in its key markets.

TSNDF Stock Performance & Valuation

Shares of the company have declined 12% on a year-to-date basis compared to the industry’s 21% decline.

Image Source: Zacks Investment Research

Consensus estimates for TSNDF’s bottom-line per share for 2026 and 2027 have improved over the past 60 days.

Image Source: Zacks Investment Research

How to Play TSNDF Stock?

TerrAscend’s recent results indicate that it is making progress, with revenues returning to growth and margins showing improvement. However, competition remains intense across the U.S. cannabis market, while the company’s debt load continues to be a concern. These factors could make it difficult for TerrAscend to sustain its recent operational gains. While recent federal reforms have provided some relief for state-licensed medical cannabis, broader reform covering adult-use cannabis is still pending, leaving investors with continued regulatory uncertainty.

Given the combination of improving fundamentals, significant competition, elevated debt and ongoing uncertainty surrounding broader federal cannabis reform, a wait-and-watch approach may be appropriate for investors at present. TSNDF currently carries a Zacks Rank #3 (Hold), which is consistent with a more cautious stance.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.